Novo Nordisk pledges $200 million to the World Diabetes Foundation, about 12% a year above its 2024 donation
The drugmaker founded the charity in 2002 and still supplies most of its money. We lined up its donations from 2011 to 2024 from the foundation's audited accounts.
By The Editors · The Game of Giving
In 2024, Novo Nordisk gave the World Diabetes Foundation DKK 120 million under the donation agreement that funds the charity's core work, exactly the cap the agreement allowed, according to the foundation's audited accounts. On November 11, 2026, the Danish drugmaker announced a new commitment: $200 million over ten years, from 2027 through 2036.
Spread evenly, the pledge is $20 million a year. At the Federal Reserve's November 6, 2026 exchange rate of 6.7016 kroner to the dollar, that is about DKK 134 million a year, or roughly 12% more than the 2024 donation, by our arithmetic. Novo Nordisk said the money will support diabetes prevention and care in low- and middle-income countries, where, the release says, around 80% of adults aged 20 to 79 with diabetes live.
What did Novo Nordisk announce?
A ten-year, fixed-dollar pledge, announced from its headquarters in Bagsværd, Denmark, three days before World Diabetes Day on November 14. The company said the length of the commitment "will give WDF greater certainty to plan for the long term."
"Lasting improvements in health don't happen overnight," said Elin Jäger, a senior vice president at Novo Nordisk who is chief of staff to the chief executive, in the announcement. Leif Fenger Jensen, the foundation's managing director, said in the same release that "the World Diabetes Foundation is grateful for this major commitment from Novo."
The release gives two examples of the foundation's work. In Tanzania, it says, more than two decades of support helped a small diabetes clinic become a government-owned national program for non-communicable diseases. In Jordan, it says, a five-year program strengthened more than 190 health facilities and trained more than 2,000 health workers.
How much has Novo Nordisk given before?
The donations have nearly doubled since 2011, according to the foundation's audited annual accounts. The foundation, known as WDF, was set up by Novo Nordisk A/S in 2002 as an independent Danish foundation with its own board, and the company's donation agreement remains its main source of income.
| Year | Donation from Novo Nordisk A/S | Basis |
|---|---|---|
| 2011 | DKK 64.7 million | 2012 audited accounts |
| 2012 | DKK 64.4 million | 2012 audited accounts |
| 2019 | DKK 86.5 million | 2020 audited accounts |
| 2020 | DKK 87.4 million | 2020 audited accounts |
| 2021 | DKK 92.2 million | 2021 audited accounts |
| 2023 | DKK 119.0 million | 2024 audited accounts |
| 2024 | DKK 120.0 million | 2024 audited accounts |
| 2027-2036 average | About DKK 134 million ($20 million) | Our conversion of the $200 million pledge |
The table leaves out money Novo Nordisk A/S earmarked for specific projects, such as DKK 12.8 million for WDF's Diabetes Compass in 2024, and gifts from the separate Novo Nordisk Foundation. The conversion assumes even yearly payments and today's exchange rate; the release gives neither a schedule nor a kroner figure, and a stronger or weaker dollar would move the comparison.
How does the current agreement work?
It is tied to sales. WDF's 2024 accounts say the donation is "calculated as 0.085% of Novo Nordisk's total diabetes care net sales," capped at DKK 120 million in 2024 and rising by DKK 1 million a year until 2026, or at 15% of the company's taxable income if that is lower. The agreement is renewed each year on a rolling basis. In 2020 the cap was DKK 91 million, according to that year's accounts.
The new pledge is stated in dollars, not as a share of sales. Novo Nordisk's release does not say whether it replaces the sales-linked formula or how it will be paid, so we cannot say yet whether the change protects WDF from a fall in diabetes sales or limits its share of a rise. In our view, the fixed figure is the point: a ten-year number a charity can plan around is worth more to its partners than a larger figure that resets every year.
Where else does WDF's money come from?
Almost entirely from the Novo Nordisk group. In 2024, WDF's total donations were DKK 200.7 million. Novo Nordisk A/S gave DKK 135.9 million of that, counting its core and earmarked donations, and the separate Novo Nordisk Foundation gave DKK 62.4 million. Together that is 99% of the total, by our arithmetic. The Novo Nordisk Foundation has also pledged WDF up to DKK 260 million over 2024 to 2030. Since 2002, WDF says, it has provided 244.4 million euros to 633 partnership projects in 121 countries.
That concentration is a risk for the clinics and health ministries WDF funds, because corporate giving moves with corporate decisions: most big companies cut giving in 2025, according to CECP. Long pledges with a fixed end date, like GiveWell's malaria target for 2027 to 2032, are one answer.
The next data point is WDF's 2025 annual accounts, which will show whether that year's donation again reached the cap. The first payment under the new pledge is due in 2027.
General information for donors and nonprofit leaders, not legal or tax advice. How we report is set out in our editorial guide.